Table 2 Sensitivity analysis of primary and secondary outcomes
Outcome | Sensitivity analyses | Studies (n) | TXA | Placebo | RR or MD | 95% CI | P value for effect | P value for heterogeneity |
|---|---|---|---|---|---|---|---|---|
Cerebrovascular accident | Studies randomized not less 100 patients | 9 | 286/2999 | 318/3011 | 0.90 | 0.78–1.05 | 0.18 | 0.64 |
Study with maximum sample size excluded | 21 | 9/1062 | 10/1084 | 0.95 | 0.43–2.10 | 0.90 | 0.86 | |
Reoperation for bleeding | Studies randomized not less 100 patients | 8 | 29/2812 | 59/2821 | 0.49 | 0.32–0.77 | < 0.01 | 0.58 |
Study with maximum sample size excluded | 15 | 17/815 | 30/814 | 0.59 | 0.34–1.04 | 0.07 | 0.72 | |
Mortality | Studies randomized not less 100 patients | 7 | 31/2870 | 36/2886 | 0.87 | 0.54–1.40 | 0.56 | 0.46 |
Study with maximum sample size excluded | 16 | 7/875 | 8/898 | 0.93 | 0.38–2.27 | 0.88 | 0.75 | |
Myocardial infarction | Studies randomized not less 100 patients | 11 | 286/2999 | 318/3011 | 0.90 | 0.78–1.05 | 0.18 | 0.64 |
Study with maximum sample size excluded | 22 | 23/1039 | 25/1045 | 0.94 | 0.55–1.61 | 0.81 | 0.8 | |
Acute renal insufficiency | Studies randomized not less 100 patients | 7 | 105/2758 | 102/2769 | 1.03 | 0.79–1.35 | 0.81 | 0.89 |
Study with maximum sample size excluded | 13 | 12/658 | 14/667 | 0.88 | 0.42–1.84 | 0.73 | 0.94 | |
Transfusion of any blood products | Studies randomized not less 100 patients | 7 | 954/2494 | 1400/2504 | 0.64 | 0.50–0.81 | < 0.01 | < 0.01 |
Study with maximum sample size excluded | 10 | 139/396 | 216/363 | 0.29 | 0.20–0.40 | < 0.01 | < 0.01 | |
Postoperative chest tube drainage in the first 24 h | Studies randomized not less 100 patients | 7 | 2824 | 2850 | -208.3 | −274.12,-142.48 | < 0.01 | < 0.01 |
Study with maximum sample size excluded | 17 | 802 | 814 | −215.42 | −259.48, −171.57 | < 0.01 | < 0.01 |